In a report released yesterday, Faisal Khurshid from Leerink Partners reiterated a Buy rating on Kymera Therapeutics (KYMR – Research ...

Leerink Partners analyst Jonathan Chang maintained a Buy rating on Molecular Partners (MOLN – Research Report) on October 22. The ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Fintel reports that on October 24, 2024, Leerink Partners initiated coverage of Tenax Therapeutics (NasdaqCM:TENX) with a ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 12.84% ...

Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

Notable insider trades include GOOD JENNIFER L, President & CEO at Trevi Therapeutics Inc (TRVI), who sold 40277 shares on Sep 05 ’24, at $3.11 each, totaling $0.13 million. On May 29 ’24, SCIASCIA ...

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH – Get Free Report) have been given a consensus recommendation of “Hold” by ...

Veracyte (NASDAQ:VCYT – Free Report) had its price objective upped by Leerink Partners from $35.00 to $40.00 in a research report report published on Thursday morning, Benzinga reports.

Leerink Partners' affiliate, MEDACorp, announced today the launch of a new division, the Center for Pharmacoeconomics (CPE), which will be dedicated to advancing the understanding of the societal ...

Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (WBAG:GILD) from Market Perform to Outperform. There are 2,828 funds or institutions reporting ...

Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Market Perform to Outperform. As of September 24, 2024, the average one ...